FTSE 100 today: Index, pound edge higher; StanChart, Revolution Beauty jump
John Richard Pinion, an officer at Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE), recently reported a significant stock transaction. On March 3, Pinion sold 14,439 shares of the company’s common stock, generating approximately $607,881. The shares were sold at a weighted average price of $42.10, with individual transaction prices ranging from $41.77 to $42.90. According to InvestingPro data, the company, currently valued at $3.8 billion, has shown strong revenue growth of 29% over the last twelve months, though analysts remain cautious about its profitability outlook.
Additionally, Pinion was involved in other transactions on March 1, acquiring 14,494 shares through a restricted stock unit (RSU) award under the company’s 2023 Incentive Plan, and converting 18,443 shares from performance stock units upon meeting performance metrics. These acquisitions were recorded with a transaction value of $0, as they were part of incentive and performance-based compensation plans.
Furthermore, on March 3, 31 shares were surrendered to cover tax withholdings due to RSU vesting, valued at $1,330 at a price of $42.92 per share.
These transactions reflect Pinion’s ongoing involvement with the company’s stock incentive programs and tax-related adjustments.
In other recent news, Ultragenyx Pharmaceutical Inc. has reported significant developments that are attracting attention from analysts and investors. The company exceeded expectations in its fourth-quarter 2024 earnings, with total revenue reaching $164.9 million, surpassing projections from both Goldman Sachs and Visible Alpha. This strong performance was driven by robust sales of its products, Crysvita and Dojolvi. In light of these results, Canaccord Genuity has raised its price target for Ultragenyx to $136 while maintaining a Buy rating, citing continued growth and demand in the company’s key franchises.
Additionally, the U.S. FDA has accepted Ultragenyx’s Biologics License Application for UX111, a gene therapy candidate for Sanfilippo syndrome type A, for Priority Review, with a decision expected by August 2025. H.C. Wainwright has reaffirmed its Buy rating with a $95 price target, highlighting this development as a critical milestone for the company. Cantor Fitzgerald has also maintained its Overweight rating and a $118 target, noting the progress in the DTX301 gene therapy program for OTC deficiency and the potential impact of setrusumab’s clinical readouts for osteogenesis imperfecta expected in mid-2025.
Goldman Sachs continues to support Ultragenyx with a Buy rating and a $78 target, emphasizing the company’s promising pipeline, including the anticipated launch of UX111 and the BLA filing for DTX401 in 2025. The analysts’ confidence in Ultragenyx’s strategy and product candidates reflects optimism about the company’s future prospects and growth trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.